relmacabtagene autoleucel

AXP000020.1 · CAR-T cell therapy

Platform
autologous CAR-T
Targets
CD19
Originator
JW Therapeutics
Sponsor
JW Therapeutics

Names

NameTypeSource
relmacabtagene autoleucelpreferred name, INNcurator, ncit
Carteyvabrandpress
JWCAR029codencit
relma-celsynonymncit

Virus

Role
Ex vivo gene transfer
Family
Retroviridae
Virus
lentivirus
Replication
non replicating
Modifications
non-replicative self-inactivating (SIN) lentiviral vector; the CAR carries an extracellular scFv from the murine CD19-specific hybridoma FMC63 with 4-1BB costimulatory and CD3 zeta signalling domains, co-expressed with a truncated EGFR (EGFRt) marker
Transgenes
anti-CD19 chimeric antigen receptor, truncated EGFR
Route
ex vivo, intravenous
Carrier
autologous T cells
Source
evidence

Cross-references

NCI Thesaurus
C155878
FDA UNII
K5CXA4X5U8

Approvals

AgencyRegionDateStatusBrandIndicationSource
NMPACN2021-09approvedCarteyvaAdults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapysource
NMPACN2022-10approvedCarteyvaAdults with follicular lymphoma refractory to, or relapsing within 24 months of, second-line or later systemic treatmentsource
NMPACN2024-08approvedCarteyvaAdults with relapsed or refractory mantle cell lymphoma; the third Chinese indication for this product and the first cell therapy approved in China for mantle cell lymphomasource

Clinical trials (20)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07326371Glofitamab Combined With CAR-T Therapy in R/R DLBCLNot yet recruitingPhase 22026-032027-0724DLBCL - Diffuse Large B Cell Lymphoma
NCT07198464Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System LymphomaNot yet recruiting2025-10-072029-10-0130Primary Central Nervous System Lymphoma (PCNSL)
NCT07077512Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell LymphomaRecruitingPhase 22025-09-152027-01-1530Follicular Lymphoma ( FL); Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL)
NCT06479356CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell LymphomaRecruitingPhase 22024-08-152025-04-3012Large B-cell Lymphoma; Non-Hodgkin Lymphoma
NCT06414135Relmacabtagene Autoleucel for the Treatment of Systemic SclerosisRecruitingPhase 12024-06-122025-056Systemic Sclerosis
NCT06365671CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic FactorsRecruitingPhase 22024-04-162026-0416B-cell Non Hodgkin Lymphoma
NCT06297408Relma-cel for Moderate to Severe Active Systemic Lupus ErythematosusUnknownPhase 12024-032025-0524Systemic Lupus Erythematosus
NCT06142188Relmacabtagene Autoleucel in Hematologic MalignanciesNot yet recruiting2023-12-282038-12-31150Follicular Lymphoma; Large B-cell Lymphoma; Lymphoma, B-Cell
NCT06876688Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell LymphomaRecruitingPhase 22023-11-302028-11-3030CNS Lymphoma
NCT06093841Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHLActive not recruitingPhase 22023-11-032024-01-2146Follicular Lymphoma Grade 3B; High-grade B-cell Lymphoma; Lymphoma, Large B-Cell, Diffuse; Mediastinal B-Cell Diffuse Large Cell Lymphoma
NCT05814848A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell LymphomaNot yet recruitingPhase 42023-06-202028-03-3113Relapsed or Refractory B-cell Lymphoma
NCT05806580Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell LymphomaRecruitingPhase 42023-05-012027-05-318Relapsed or Refractory B-cell Lymphoma
NCT05765006CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus ErythematosusUnknownPhase 12023-02-242024-12-3024Systemic Lupus Erythematosus
NCT05590221Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell LymphomaUnknownPhase 22023-01-032024-02-1020B-cell Lymphoma
NCT06142175Relmacabtagene Autoleucel in Patients With LBCLUnknown2022-12-282024-12-31200Large B-cell Lymphoma
NCT05370547Chidamide Bridging for CAR-T TherapyUnknownPhase 1/22022-05-252024-06-30120Non Hodgkin's Lymphoma
NCT05259813Phase I Study of JWCAR029 in Subjects With R/R CLL/SLLWithdrawnPhase 12022-02-282023-01-310Leukemia, Lymphocytic, Chronic, B-Cell
NCT04812691CD19-targeted CAR T Cells (JWCAR029) for Primary Refractory Diffuse Large B Cell LymphomaCompletedPhase 12020-07-102021-06-3012Diffuse Large B Cell Lymphoma
NCT03355859Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaUnknownPhase 12018-01-052019-1210Non Hodgkin Lymphoma
NCT03344367Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaUnknownPhase 12017-11-162019-1020Non Hodgkin Lymphoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40811825Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.Blood advances2026name in title: relmacabtagene autoleucel
PMID 40104957Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching-Adjusted Indirect Analysis.Hematological oncology2025name in title: relmacabtagene autoleucel
PMID 40386685Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial.EClinicalMedicine2025cited by trial NCT05765006
PMID 40888120Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study.British journal of haematology2025name in title: relmacabtagene autoleucel
PMID 41037957Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study.Journal of autoimmunity2025name in title: relmacabtagene autoleucel
PMID 38802271Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China.Journal for immunotherapy of cancer2024name in title: relmacabtagene autoleucel
PMID 38890370Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma.Nature communications2024name in abstract: relmacabtagene autoleucel
PMID 36477110Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.Bone marrow transplantation2023name in title: relmacabtagene autoleucel
PMID 36842849Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study.Cytotherapy2023name in title: relmacabtagene autoleucel
PMID 38143763Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R CD20-negative transformed follicular lymphoma with TP53 mutation.Frontiers in immunology2023name in abstract: relmacabtagene autoleucel
PMID 36053875Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial.American journal of hematology2022name in title: relmacabtagene autoleucel
PMID 36109639Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.Nature medicine2022cited by trial NCT06297408
PMID 33382529Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.Cancer medicine2021name in title: relmacabtagene autoleucel
PMID 34515338Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.The Cochrane database of systematic reviews2021cited by trial NCT03344367
PMID 31444250Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research2019cited by trial NCT03355859
PMID 3005930Radionuclide scans to define patterns of occult myonecrosis.New Jersey medicine : the journal of the Medical Society of New Jersey1986cited by trial NCT05765006

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41396346Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review.PharmacoEconomics - open2026name in abstract: relmacabtagene autoleucel
PMID 42223209Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis.Arthritis & rheumatology (Hoboken, N.J.)2026name in abstract: relma-cel
PMID 41003738Clinical outcome and immunophenotype of axicabtagene ciloleucel (axi-cel) and relmacabtagene autoleucel (relma-cel) in relapsed/refractory large B-Cell lymphoma on Chinese population: a single-center experience.Annals of hematology2025name in title: relmacabtagene autoleucel
PMID 38641057Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2024name in abstract: relmacabtagene autoleucel
PMID 39217529CD19 CAR-T treatment shows limited efficacy in r/r DLBCL with double expression and TP53 alterations.Cytotherapy2024name in abstract: relma-cel
PMID 37209540Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China.Value in health regional issues2023name in title: relmacabtagene autoleucel
PMID 37356080Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.Applied health economics and health policy2023name in abstract: relmacabtagene autoleucel

Notes

Same CD19 CAR construct as liso-cel, but JW's own process (no separate CD4/CD8 trains); separate INN, so separate program.

How to cite

relmacabtagene autoleucel (AXP000020.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000020.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.